The research sponsors of the Champion Programme (CP), and Custodix, agreed at the outset to collaborate on a joint and shared evaluation that would help generate evidence of the value of this innovative platform and of this novel method for optimising protocols and facilitating recruitment into studies. It is intended that this evidence will be used internally by each of the participating research sponsors to scale up future investments in this platform, will be used by Custodix (with agreed levels of de-identification and aggregation) to support their promotion of InSite to sponsors and hospitals, and will be used by i~HD to promote the positive value of this kind of clinical research ecosystem and also to better understand its strengths and weaknesses. The evaluation method and metrics will be generic to any clinical research platform. None of the criteria and indicators within the evaluation framework are specific to one platform provider. Methodologically, the evaluation of the CP consists of two tracks: a programme evaluation – to understand better drivers, incentives and barriers to join and implement the CP; a technology assessment – to capture usage and technical implementation of the platform. The evaluation framework comprises costs and benefits, monetary and non-monetary, for two stakeholder groups: research sponsors and hospitals.